{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Number of participants with response post-infusion as assessed by international uniform response criteria","groups":[{"description":"Participants who received cytoreductive chemotherapy followed by infusion of lentivirus-mediated genetically engineered NY-ESO-1ᶜ²⁵⁹T (Target dose: 1-10 billion cells)","id":"OG000","title":"NY-ESO-1ᶜ²⁵⁹T Cells Administered IV"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received NY-ESO-1ᶜ²⁵⁹T","reportingStatus":"POSTED","timeFrame":"180 days","title":"Evaluate the Direct Anti-tumor Activity of NY-ESO-1ᶜ²⁵⁹T","type":"SECONDARY","unitOfMeasure":"Participants"}